News: brad.haugaard@gmail.com   •  Restaurants   •  Library Catalog   •  Library Activities  •  Facebook / Twitter / RSS

Monrovia's Xencor Reports a Financially Successful 2021

Monrovia's Xencor, which develops drugs for the treatment of cancer and autoimmune diseases, reported a 2021 net income of  $82.6 million, or $1.37 per share, compared to a net loss of $69.3 million, or $(1.21) per share for the previous year. The company attributes the higher income primarily "to increased royalties and revenue recognized from collaborations."

- Brad Haugaard

No comments:

Post a Comment